CD274 and lung carcinoma: Recent studies have revealed that the detection of mutational signatures from panel sequencing data is available in patients with breast, ovarian, and lung cancer as well as melanoma, to determine their response to PARP and PD-L1 inhibitors (Gulhan et al., 2019; Färkkilä et al., 2020; Chong et al., 2021).